Lv1
90 积分 2023-07-18 加入
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study
17小时前
待确认
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?
1天前
待确认
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
1天前
待确认
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases
1天前
待确认
皖公网安备34019202002308
